Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorescein sodium + benoxinate hydrochloride is a fixed-dose combination ophthalmic solution used primarily for diagnostic and minor therapeutic procedures in the eye. It combines fluorescein sodium, a disclosing (staining) agent that highlights corneal defects or foreign bodies under blue light, with benoxinate hydrochloride, a local ester anesthetic that provides rapid-onset but short-duration topical anesthesia. This combination facilitates procedures such as tonometry, gonioscopy, removal of corneal foreign bodies, and fitting of hard contact lenses by both staining the ocular surface and numbing the eye to reduce discomfort[1][2][3][4][5]. The product is available in various strengths (commonly 0.25–0.3% fluorescein sodium with 0.4% benoxinate hydrochloride)[1][2][6]. Prolonged use may cause corneal toxicity; it is contraindicated in patients with hypersensitivity to any component[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorescein sodium + benoxinate hydrochloride.